XYLOCAINE OINTMENT 5%

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

LIDOCAINE

থেকে পাওয়া:

ASPEN PHARMACARE CANADA INC.

এটিসি কোড:

D04AB01

INN (আন্তর্জাতিক নাম):

LIDOCAINE

ডোজ:

5%

ফার্মাসিউটিকাল ফর্ম:

OINTMENT

রচনা:

LIDOCAINE 5%

প্রশাসন রুট:

TOPICAL

প্যাকেজ ইউনিট:

35G

প্রেসক্রিপশন টাইপ:

Ethical

থেরাপিউটিক এলাকা:

ANTIPRURITICS AND LOCAL ANESTHETICS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0103565001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2000-05-11

পণ্য বৈশিষ্ট্য

_XYLOCAINE_
_® _
_Ointment (lidocaine) Page 1 of 26 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
XYLOCAINE
® OINTMENT 5%
lidocaine ointment
Ointment, 50 mg/g, Topical
USP
Topical anesthetic
Aspen Pharmacare Canada Inc.
8-1155 North Service Road West
Oakville, Ontario, L6M 3E3
Date of Initial Authorization:
DEC 31, 1954
Date of Revision:
OCT 11, 2022
Submission Control Number: 263488
Trademarks are owned by or licensed to the Aspen Group of companies.
_© 2022 Aspen Group of companies or its licensor. All rights
reserved. _
_ _
_XYLOCAINE_
_® _
_Ointment (lidocaine) _
_Page 2 of 26 _
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.2.1
Special Populations
................................................................